The Liberian case from 2015 highlights a lingering threat that the DRC will face after its outbreak is declared over.
Public Health England (PHE) yesterday released its provisional seasonal flu vaccine effectiveness (VE) estimates for the 2017-18 flu season, which revealed low overall effectiveness and no protection against H3N2, but variable findings in different age-groups.
A phase 3 study of the novel antiviral baloxavir marboxil suggests that it reduces symptoms in people at high risk of flu complications, Roche announced today.
The US Food and Drug Administration (FDA) today approved TPOXX (tecovirimat), made by SIGA Technologies, as the first drug with an indication for treating smallpox, a disease that has been eradicated but could still be used as a bioweapon.
Depression, headaches, and insomnia are just some of the often debilitating symptoms.
A study published in Vaccine shows that even small doses of the yellow fever vaccine are likely to offer protection against the virus for up to 8 years after vaccination. The information reassures countries like Brazil, who have used fractional dosing in an effort to stretch supplies of the vaccine during recent outbreaks.
The Indiana State Department of Health (ISDH) announced the first case of variant influenza H3N2 (H3N2v) detected this year in a county fairgoer who was in close proximity to pigs. The Centers for Disease control and Prevention (CDC) confirmed the infection on Jun 29.
The Democratic Republic of the Congo's (DRC's) health ministry said today that all contacts of the last confirmed case have completed their 21-day monitoring periods with none showing any signs of illness, marking the beginning of the countdown to the end of the nation's ninth Ebola outbreak.
In a separate report, researchers from Liberia weigh in on urban spread in the DRC and recommend strategies for reducing that type of Ebola transmission.
No new lab-confirmed Ebola infections were reported from the Democratic Republic of the Congo (DRC) over the past 3 days, though surveillance workers continue to report more suspected cases from the remote hot spots, while tests rule out earlier suspected cases.
